Effects of St John's Wort and Hypericin on Cytotoxicity of Anticancer Drugs

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 5, 2002, Pages 467-474

  Wada, Atsushi ^a   Hirai, Midori ^a   Kimura, Takashi ^a   Sakaeda, Toshiyuki ^b   Ohmoto, Nobuko ^b   Zhou, Jie ^b   Nakamura, Tsutomu ^b   Okumura, Katsuhiko ^b   Takara, Kohji ^c   Kobayashi, Hironao ^d   Okamura, Noboru ^d   Yagami, Tatsurou ^d  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

down regulation of MDR1 mRNA; hypericin; inhibition of MDR1 mediated transport; reversal of multidrug resistance; St John's wort

Indexed keywords

EID: 28244477789     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.467     Document Type: Article

References (26)

1. Barnes, J., Anderson, L. A. and Phillipson, J. D.: St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol., 53: 583-600 (2001).
2. Newall, C. A., Anderson, L. A., Phillipson, J. D. and Herbal Medicines: A guide for healthcare professionals. 1st edn. London: Pharmaceutical Press. (1996).
3. Beckmann, S. E., Roger, W. S. and Switzer, J.: Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy, 20: 568-574 (2000).
4. Fugh-Berman A.: Herb-drug interactions. Lancet, 355: 134-138 (2000).
5. Fugh-Berman, A. and Ernst, E.: Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol., 52: 587-595 (2001).
6. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I.: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther., 66: 338-345 (1999).
7. Dürr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J. and Fattinger, K.: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 68: 598-604 (2000).
8. Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L. and Abul-Ezz, S. R.: Drug interaction between St. John's wort and cyclosporine. Ann. Pharmacother., 34: 1013-1016 (2000).
9. Breidenbach, T., Hoffmann, M. W., Becker, T., Schlitt, H. and Klempnauer, J.: Drug interaction of St John's wort with cyclosporin. Lancet, 355: 1912 (2000).
10. Ruschitzka, F., Meier, P. J., Turina, M., Luscher, T. F. and Noll, G.: Acute heart transplant rejection due to Saint John's wort. Lancet, 355: 548-549 (2000).
11. Piscitelli, S., Burstein, A. H., Chaitt, D., Alfaro, R. M. and Falloon, J.: Indinavir concentrations and St John's wort. Lancet, 355: 547-548 (2000).
12. Nebel, A., Schneider, B. J., Baker, R. K. and Kroll, D. J.: Potential metabolic interaction between St. John's wort and theophylline. Ann. Pharmacother., 33: 502 (1999).
13. Perloff, M. D., von Moltke, L. L., Stormer, E., Shader, R. I. and Greenblatt, D. J.: Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol., 134: 1601-1608 (2001).
14. Wang, Z, Hamman, M. A., Huang, S. M., Lesko, L. J. and Hall, S. D.: Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther., 71: 414-20 (2002).
15. Bradshaw, D. M., Arceci, R. J.: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol., 16: 3674-3690 (1998).
16. Iida, N., Takara, K., Ohmoto, N., Nakamura, T., Kimura, T., Wada, A., Hirai, M., Sakaeda, T. and Okumura, K.: Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells. Biol. Pharm. Bull., 24: 1032-1036 (2001).
17. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. and Hori, R.: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther., 263: 840-845 (1992).
18. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R.: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 267: 24248-24252 (1992).
19. Takara, K., Kakumoto, M., Tanigawara, Y., Funakoshi, J., Sakaeda, T. and Okumura, K.: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci., 70: 1491-1500 (2002).
20. Kirakosyan, A., Hayashi, H., Inoue, K., Charchoglyan, A. and Vardapetyan, H.: Stimulation of the production of hypericins by mannan in Hypericum perforatum shoot cultures. Phytochemistry, 53: 345-348 (2000).
21. Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T. and Bates, S. E.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46: 627-638 (1994).
22. Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L. B., Dickstein, B., Lee, J. S., Elgemeie, G. H., Stein, W. D. and Bates, S. E.: P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol., 51: 1024-1033 (1997).
23. Takara, K., Tsujimoto, M., Ohnishi, N. and Yokoyama, T.: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun., 292: 190-194 (2002).
24. Sakaeda, T., Nakamura, T., Hirai, M., Kimura, T., Wada, A., Yagami, T., Kobayashi, H., Nagata, S., Okamura, N., Yoshikawa, T., Shirakawa, T., Gotoh, A., Matsuo, M. and Okumura, K.: MDR1 up-regulated by Apoptotic stimuli suppresses apoptotic signaling. Pharm. Res., 19: 1323-1329 (2002).
25. Kerb, R., Brockmöller, J., Staffeldt, B., Ploch, M. and Roots, I.: Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob. Agents Chemother., 40: 2087-2093 (1996).
26. Sakaeda, T., Nakamura, T., and Okumura, K.: MDR1 genotype-related pharmacokinetics and phrmacodynamics. Biol. Pharm. Bull., 25: 1391-1400 (2002).